| ²é¿´: 793 | »Ø¸´: 7 | |||
caohoupingľ³æ (ÕýʽдÊÖ)
|
[ÇóÖú]
ÇâÂÈàçàºEP7.6ÖÊÁ¿±ê×¼
|
| ÇâÂÈàçàºEP7.6ÖÊÁ¿±ê×¼£¬ÇóÖú£¡Ð»Ð»¸÷λÁË |
» ²ÂÄãϲ»¶
ÈçºÎ¸ßЧµÄ²âÁ¿ÏÙ²¡¶¾µÄÁ£¾¶ºÍµçλ
ÒѾÓÐ0È˻ظ´
26ÔÚÖ°É격¡ªÉúÎïÓëÒ½Ò©¡ª¿¹Ìå/ADCÒ©Îï·½Ïò£¬½Õ㻦£¬ÓÐÏîÄ¿£¬¿É´ø×Ê¡£
ÒѾÓÐ1È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ68È˻ظ´
288·ÖÇóµ÷¼Á
ÒѾÓÐ0È˻ظ´
292ҩѧµ÷¼Á
ÒѾÓÐ1È˻ظ´
Ò»Ö¾Ô¸ËÕÖÝ´óѧ ÉúÎï¼¼ÊõÓ빤³Ì£¨086001£© ³õÊÔ323·Ö£¬Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
ÈýÄêʵÑéÊÒ¹¤×÷¾Àú£¬Ò»Ö¾Ô¸»ªÖÐũҵ´óѧ΢ÉúÎ×Ü·Ö288Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
070700Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
Çóµ÷¼Á×Ü·Ö327
ÒѾÓÐ1È˻ظ´
so0325
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 56 (³õÖÐÉú)
- ½ð±Ò: 1734.4
- ºì»¨: 3
- Ìû×Ó: 290
- ÔÚÏß: 120.8Сʱ
- ³æºÅ: 401234
- ×¢²á: 2007-06-13
- ÐÔ±ð: MM
- רҵ: ºÏ³ÉÒ©Îﻯѧ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
ºÓ±ßµÄ«Î: ½ð±Ò+1, ¸ÐлÄãµÄ»ØÌû½»Á÷~ 2013-07-08 15:22:52
ºÓ±ßµÄ«Î: »ØÌûÖö¥ 2013-07-08 15:22:57
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
ºÓ±ßµÄ«Î: ½ð±Ò+1, ¸ÐлÄãµÄ»ØÌû½»Á÷~ 2013-07-08 15:22:52
ºÓ±ßµÄ«Î: »ØÌûÖö¥ 2013-07-08 15:22:57
| BP2013µÄ¿ÉÒÔ²»£¬»ù±¾ÊÇÕÕ×ÅEP°ÇÏÂÀ´µÄ |
» ±¾Ìû¸½¼þ×ÊÔ´Áбí
-
»¶Ó¼à¶½ºÍ·´À¡£ºÐ¡Ä¾³æ½öÌṩ½»Á÷ƽ̨£¬²»¶Ô¸ÃÄÚÈݸºÔð¡£
±¾ÄÚÈÝÓÉÓû§×ÔÖ÷·¢²¼£¬Èç¹ûÆäÄÚÈÝÉæ¼°µ½ÖªÊ¶²úȨÎÊÌ⣬ÆäÔðÈÎÔÚÓÚÓû§±¾ÈË£¬Èç¶Ô°æÈ¨ÓÐÒìÒ飬ÇëÁªÏµÓÊÏ䣺xiaomuchong@tal.com - ¸½¼þ 1 : ÇâÂÈàçàº-BP2013.rar
2013-07-08 14:20:38, 120.74 K
2Â¥2013-07-08 14:20:51
caohouping
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 16 (СѧÉú)
- ½ð±Ò: 4673.1
- ºì»¨: 12
- Ìû×Ó: 991
- ÔÚÏß: 418.6Сʱ
- ³æºÅ: 1115654
- ×¢²á: 2010-10-07
- ÐÔ±ð: GG
- רҵ: »·¾³Î¢ÉúÎïѧ
3Â¥2013-07-08 17:55:23
caohouping
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 16 (СѧÉú)
- ½ð±Ò: 4673.1
- ºì»¨: 12
- Ìû×Ó: 991
- ÔÚÏß: 418.6Сʱ
- ³æºÅ: 1115654
- ×¢²á: 2010-10-07
- ÐÔ±ð: GG
- רҵ: »·¾³Î¢ÉúÎïѧ
4Â¥2013-07-08 17:55:52
caohouping
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 16 (СѧÉú)
- ½ð±Ò: 4673.1
- ºì»¨: 12
- Ìû×Ó: 991
- ÔÚÏß: 418.6Сʱ
- ³æºÅ: 1115654
- ×¢²á: 2010-10-07
- ÐÔ±ð: GG
- רҵ: »·¾³Î¢ÉúÎïѧ
|
SUPPLEMENT 7.6 Related substances: in line with the general monograph Substances for pharmaceutical use (2034), an explicit acceptance criterion for unspecified impurities has been introduced; in addition, relative retentions of specified impurities are now given, and a peak identification CRS has been introduced to allow the identification of specified impurities. SUPPLEMENT 7.4 Content: lower limit updated to reflect change in assay method. Assay: titration replaced by LC. SUPPLEMENT 6.4 Characters: the substance shows polymorphism. PUBLICATION 6.0 Identification: IR spectra might show differences that disappear after recrystallisation: corresponding statement added. |
5Â¥2013-07-08 17:57:03
caohouping
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 16 (СѧÉú)
- ½ð±Ò: 4673.1
- ºì»¨: 12
- Ìû×Ó: 991
- ÔÚÏß: 418.6Сʱ
- ³æºÅ: 1115654
- ×¢²á: 2010-10-07
- ÐÔ±ð: GG
- רҵ: »·¾³Î¢ÉúÎïѧ
|
New for 2013 Legally effective from 1 January 2013 41 new BP monographs 40 new European Pharmacopoeia monographs 619 amended monographs 6 new and 1 amended Infrared Reference Spectra European Pharmacopoeia 7th edition material up to and including Supplement 7.5 Free in-year updates in January, April and July to harmonise with the European Pharmacopoeia |
6Â¥2013-07-08 17:57:57
³ÕÒÄ×ÓÆ¤
°æÖ÷ (ÎÄ̳¾«Ó¢)
ÀÏÆ¦
- DRDEPI: 8
- Ó¦Öú: 2016 (½²Ê¦)
- ¹ó±ö: 5.368
- ½ð±Ò: 54487.3
- É¢½ð: 41688
- ºì»¨: 303
- ɳ·¢: 1206
- Ìû×Ó: 32611
- ÔÚÏß: 4303.7Сʱ
- ³æºÅ: 674536
- ×¢²á: 2008-12-14
- ÐÔ±ð: GG
- רҵ: ÎÞÉñÂÛ
- ¹ÜϽ: ÈËÎÄÉç¿Æ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
yuanahen: ½ð±Ò+2, ¸Ðл²ÎÓ룬ÆÚ´ý¸ü¶àÓмÛÖµµÄÌû×Ó 2013-07-09 08:51:50
caohouping: ½ð±Ò+5, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, ллÀÏ´ó 2013-07-09 09:48:20
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
yuanahen: ½ð±Ò+2, ¸Ðл²ÎÓ룬ÆÚ´ý¸ü¶àÓмÛÖµµÄÌû×Ó 2013-07-09 08:51:50
caohouping: ½ð±Ò+5, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, ллÀÏ´ó 2013-07-09 09:48:20

7Â¥2013-07-09 08:44:15
fanger-lei
гæ (³õÈëÎÄ̳)
- Ó¦Öú: 7 (Ó×¶ùÔ°)
- ½ð±Ò: 188.5
- ºì»¨: 1
- Ìû×Ó: 23
- ÔÚÏß: 5.6Сʱ
- ³æºÅ: 2032780
- ×¢²á: 2012-09-27
- ÐÔ±ð: MM
- רҵ: Ò©¼Áѧ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
caohouping: ½ð±Ò+5, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, ллMM 2013-07-09 09:48:41
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
caohouping: ½ð±Ò+5, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, ллMM 2013-07-09 09:48:41
| ÕÒÁËһϣ¬ÓÐÁ½¸ö°æ±¾¡£Äã¿´¿´Äܲ»ÄܰﵽÄã |
8Â¥2013-07-09 08:55:19













»Ø¸´´ËÂ¥